Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period

Sensitivity and specificity of epstein‐barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three‐year institutional review

“…One study, however, showed that there was only a limited correlation between the level of the EBV IgA-VCA titer and the overall stage of the disease at presentation. 9 There has also not been a dramatic shift toward earlier presentation of NPC in Hong Kong. In our group of patients with NPC, there existed only a weak correlation (r = 0.19) of the EBV IgA-VCA titer to the stage of NPC.…”

Antibodies against Epstein–Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology

“…In comparison with healthy EBV carriers, NPC patients typically show strong IgG and especially IgA reactivities to lytic antigens (Fachiroh et al, 2004;Henle & Henle, 1976), so an EBV serological assay could facilitate diagnosis and prognosis of NPC. IgA antibody titres against the EBV viral capsid antigen (VCA) and the diffused early antigens (EA-D) are regularly tested in many clinical centres (Deng et al, 1995; Hadar et al, 1986;Henle & Henle, 1976;Ho et al, 1998 et al, 2004). However, few of them have been shown as valuable markers for NPC diagnosis.…”

Development of a time-resolved fluoroimmunoassay for Epstein–Barr virus viral capsid antigen IgA antibody in human serum

“…Non-invasive screening of NPC usually involves serological testing for the presence of IgA antibodies to EBV VCA (Li et al, 2010). Many studies have indicated that VCA-IgA might be a biomarker for the screening, early diagnosis and differential diagnosis of NPC (Chan, 2010; Deng et al, 1995;Henle and Henle, 1976;Ho et al, 1976Ho et al, , 1998. In NPC screening programs, patients positive for VCA-IgA antibodies should be closely monitored and receive strict clinical examinations and close follow-up (Yu et al, 2011).…”